H. Lundbeck Toekomstige groei

Future criteriumcontroles 2/6

H. Lundbeck zal naar verwachting groeien in winst en omzet met respectievelijk 8.6% en 3.7% per jaar. De winst per aandeel zal naar verwachting groeien met 8.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.5% zijn.

Belangrijke informatie

8.6%

Groei van de winst

8.8%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	15.7%
Inkomstengroei	3.7%
Toekomstig rendement op eigen vermogen	10.5%
Dekking van analisten	Good
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

WBAG:LUNB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (DKK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	24,638	4,074	5,156	5,624	9
12/31/2025	23,339	3,581	4,774	5,183	10
12/31/2024	22,053	3,039	4,316	4,689	9
9/30/2024	21,441	2,687	4,936	5,421	N/A
6/30/2024	20,671	2,586	4,128	4,609	N/A
3/31/2024	20,239	2,298	4,245	4,791	N/A
12/31/2023	19,912	2,290	3,579	4,080	N/A
9/30/2023	19,614	2,467	3,528	4,426	N/A
6/30/2023	19,381	2,479	3,523	4,457	N/A
3/31/2023	18,918	2,384	3,292	4,102	N/A
12/31/2022	18,246	1,916	2,699	3,519	N/A
9/30/2022	17,619	1,603	2,051	2,615	N/A
6/30/2022	16,913	1,236	1,744	2,313	N/A
3/31/2022	16,398	1,109	1,344	1,959	N/A
12/31/2021	16,299	1,318	1,660	2,272	N/A
9/30/2021	16,521	1,873	2,405	2,949	N/A
6/30/2021	16,971	1,965	2,379	2,912	N/A
3/31/2021	17,381	2,110	3,263	3,757	N/A
12/31/2020	17,672	1,581	3,359	3,837	N/A
9/30/2020	17,818	904	2,713	3,171	N/A
6/30/2020	17,490	1,242	2,910	3,354	N/A
3/31/2020	17,366	1,507	1,502	1,960	N/A
12/31/2019	17,036	2,313	2,165	2,609	N/A
9/30/2019	16,811	3,091	3,210	3,621	N/A
6/30/2019	17,309	3,395	2,736	3,462	N/A
3/31/2019	17,766	3,606	4,100	4,815	N/A
12/31/2018	18,117	3,907	5,277	5,981	N/A
9/30/2018	18,313	3,806	5,057	5,922	N/A
6/30/2018	18,028	3,627	N/A	6,197	N/A
3/31/2018	17,608	3,236	N/A	5,397	N/A
12/31/2017	17,234	2,624	N/A	4,045	N/A
9/30/2017	17,007	2,544	N/A	3,731	N/A
6/30/2017	16,607	1,988	N/A	3,551	N/A
3/31/2017	16,075	1,612	N/A	3,420	N/A
12/31/2016	15,634	1,211	N/A	3,126	N/A
9/30/2016	15,202	290	N/A	4,158	N/A
6/30/2016	14,923	-1,289	N/A	2,755	N/A
3/31/2016	14,801	-5,427	N/A	936	N/A
12/31/2015	14,594	-5,694	N/A	197	N/A
9/30/2015	14,108	-5,879	N/A	-1,330	N/A
6/30/2015	13,625	-4,615	N/A	-464	N/A
3/31/2015	13,444	-565	N/A	1,379	N/A
12/31/2014	13,468	-153	N/A	1,610	N/A
9/30/2014	13,808	503	N/A	2,601	N/A
6/30/2014	14,181	765	N/A	2,095	N/A
3/31/2014	14,269	119	N/A	2,982	N/A
12/31/2013	15,258	855	N/A	3,760	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei LUNB ( 8.6% per jaar) ligt boven de spaarquote ( 1.4% ).

Winst versus markt: De winst van LUNB ( 8.6% per jaar) zal naar verwachting langzamer groeien dan de markt Austrian ( 9.1% per jaar).

Hoge groeiwinsten: De winst van LUNB zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van LUNB ( 3.7% per jaar) zal naar verwachting sneller groeien dan de markt Austrian ( 0.7% per jaar).

Hoge groei-inkomsten: De omzet van LUNB ( 3.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen LUNB zal naar verwachting over 3 jaar laag zijn ( 10.5 %).

H. Lundbeck Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Recent updates

Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023)

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Second quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.60 in 2Q 2023)

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

Dividend of kr.0.70 announced

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven